~267 spots leftby Aug 2025

CagriSema vs. Tirzepatide for Weight Loss in Obesity

Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Novo Nordisk A/S
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial tests if a new combination of two drugs, given regularly, helps people lose weight better than another treatment. It targets individuals needing to lower their body weight by helping them feel less hungry and manage their weight. Two different drugs are being investigated as options for weight management.

Eligibility Criteria

This trial is for adults with obesity, defined as having a BMI of 30 or higher. It's not suitable for people who have diabetes (type 1 or type 2) or those with an HbA1c level of 6.5% or more, which indicates high blood sugar levels.

Exclusion Criteria

I have a history of diabetes.

Treatment Details

The study compares the effectiveness of CagriSema—a combination of two drugs, Cagrilintide and Semaglutide—with Tirzepatide in helping individuals lose weight. Participants will self-administer weekly injections using a pen injector over approximately one and a half years.
2Treatment groups
Experimental Treatment
Active Control
Group I: CagriSema 2.4 mg/2.4 mgExperimental Treatment2 Interventions
Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 72 weeks.
Group II: Tirzepatide 15 mgActive Control1 Intervention
Participants will receive 15 mg tirzepatide subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 72 weeks.

Find a clinic near you

Research locations nearbySelect from list below to view details:
Novo Nordisk Investigational SiteDallas, TX
Novo Nordisk Investigational SiteChapel Hill, NC
Novo Nordisk Investigational SiteMontgomery, AL
Novo Nordisk Investigational SiteHonolulu, HI
More Trial Locations
Loading ...

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor

References